OPEN ACCESS

Saudi Journal of Medicine
Abbreviated Key Title: Saudi J Med
ISSN 2518-3389 (Print) | ISSN 2518-3397 (Online)
Scholars Middle East Publishers, Dubai, United Arab Emirates
Journal homepage: https://saudijournals.com

Review Article

Erectile Dysfunction in Adults: A Review of Neurological Causes and Risk Factor Analysis

Dr. S M Saadi[1*], Dr. Rehnuma Taher Fariha[2], Dr. Rabeya Sultana Jui[3], Dr. S M Sadlee[4], Dr. Pijush Majumder[5], Dr. Muhammad Abdur Rouf[6], Dr. Biplob Kumar Roy[7], Dr. Md. Nazrul Islam[8], Dr. Amitabh Sarkar[9]

[1]Senior Consultant, Department of Neurology, SHIP International Hospital, Dhaka, Bangladesh
[2]Junior Consultant, Department of Respiratory Medicine, United Hospital Ltd, Dhaka, Bangladesh
[3]Clinical Assistant, General High Dependency Unit, United Hospital Ltd, Dhaka, Bangladesh
[4]Associate Consultant, Department of Neurology, United Hospital Ltd, Dhaka, Bangladesh
[5]Registrar, Department of Neurology, Chittagong Medical College Hospital, Chattogram, Bangladesh
[6]Associate Professor, Department of Medicine, Mymensingh Medical College, Mymensingh, Bangladesh
[7]Professor, Department Head, Neurology, Sylhet M. A. G. Osmani Medical College, Sylhet, Bangladesh
[8]Professor, Department of Neurology, Parkview Medical College and Hospital, Sylhet, Bangladesh
[9]Associate Professor, Department of Medicine, Sher-E-Bangla Medical College, Barishal, Bangladesh

DOI: 10.36348/sjm.2024.v09i07.007 | **Received:** 25.05.2024 | **Accepted:** 02.07.2024 | **Published:** 15.07.2024

***Corresponding Author:** Dr. S M Saadi
Senior Consultant, Department of Neurology, SHIP International Hospital, Dhaka, Bangladesh

Abstract

Erectile dysfunction (ED) is a prevalent condition affecting adult men globally, characterized by the inability to achieve or maintain an erection sufficient for sexual intercourse. Neurological causes, including multiple sclerosis, Parkinson's disease, ischemic stroke, congenital spinal abnormalities, and spinal cord injuries, disrupt neural pathways essential for erectile function. Additionally, chronic conditions such as diabetes mellitus, hypertension, hyperlipidemia, and cardiovascular diseases, along with lifestyle factors like smoking and alcohol consumption, exacerbate ED by compromising vascular health. Psychological stressors further complicate the etiology of ED. Pelvic surgeries, cavernous nerve injuries, and certain medications, including antihypertensives and antidepressants, contribute to ED progression. Effective management requires addressing these neurological, vascular, hormonal, and psychological factors, necessitating a multidisciplinary approach involving specialists such as neurologists, urologists, endocrinologists, and mental health professionals. This review highlights the complex interplay between neurological disorders, systemic conditions, and lifestyle factors in the pathophysiology of ED, emphasizing the need for tailored treatment strategies targeting the underlying contributors to improve patient outcomes.

Keywords: Erectile dysfunction (ED), neurological causes, pelvic surgeries.

INTRODUCTION

Erectile dysfunction (ED) is a prevalent condition affecting millions of adult men worldwide, characterized by the consistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. While ED is often associated with advancing age, it can affect men of all ages, significantly impacting their quality of life and psychological well-being. Understanding the underlying neurological causes and risk factors associated with ED is crucial for effective management and intervention strategies [1-3].

The neurological system plays a central role in the complex process of penile erection, involving a delicate interplay between vascular, hormonal, and neurological factors. Various neurological disorders can disrupt this intricate mechanism, leading to ED. Conditions such as multiple sclerosis (MS), Parkinson's disease, stroke, spinal cord injury, and peripheral neuropathy can impair neural signaling pathways responsible for initiating and maintaining erection. These disorders may disrupt both central (brain and spinal cord) and peripheral (nerves outside the central nervous system) aspects of the erectile process, contributing to ED pathology [4-7].

Beyond specific neurological disorders, several risk factors increase the likelihood of developing ED. Diabetes mellitus, a prevalent metabolic disorder, is strongly associated with ED due to its detrimental effects on vascular and neurological function. Chronic conditions such as hypertension, hyperlipidemia, and cardiovascular disease can also impair blood flow to the penis, compromising erectile function. Additionally, lifestyle factors including smoking, excessive alcohol consumption, obesity, and sedentary behavior contribute to ED risk by promoting vascular damage, hormonal imbalance, and neurological dysfunction [8-11]. Psychological factors such as stress, anxiety, depression, and relationship issues further exacerbate ED, highlighting the complex interplay between neurological, psychological, and physiological factors in its etiology.

The pathophysiology of ED involves a multifaceted interaction between neurological, vascular, hormonal, and psychosocial factors. Neurological abnormalities disrupt the intricate neural circuitry essential for penile erection, leading to impaired erectile function. Vascular compromise further exacerbates this dysfunction by limiting blood flow to the penis, while hormonal imbalances and psychological stressors contribute to the overall burden of ED [12]. To understand the interconnected nature of these factors is essential for the thorough evaluation and management of ED, emphasizing the need for a multidisciplinary approach that includes expertise from neurologists, urologists, endocrinologists, and mental health professionals.

Causes

Multiple Sclerosis

ED in individuals with MS manifests as the consistent inability to achieve or maintain an erection sufficient for sexual intercourse. This complication can significantly impair quality of life, leading to frustration, anxiety, and relationship strain. The prevalence of ED in MS patients is notably higher compared to the general population, underscoring the complex interplay between neurological pathology and sexual function in this population [12].

The pathophysiology of ED in MS involves multifactorial mechanisms stemming from both central and peripheral neurological dysfunction. MS-related demyelination and neuronal damage disrupt the intricate neural pathways responsible for initiating and sustaining penile erection. Dysfunction within the autonomic nervous system, particularly sympathetic and parasympathetic pathways, impairs the physiological processes necessary for erectile function, including vascular regulation and smooth muscle relaxation. Additionally, MS-associated lesions in the brain and spinal cord can disrupt neurotransmitter signaling, hormonal regulation, and sensory perception, further contributing to ED pathology [13-14].

Several studies have identified MS as a significant risk factor for ED, elucidating the complex relationship between neurological dysfunction and sexual impairment in MS patients. A systematic review highlighted a high prevalence of sexual dysfunction, including ED, in individuals with MS, with reported rates ranging from 40% to 91% [15]. Furthermore, a longitudinal study demonstrated a significant association between MS-related disability and the severity of ED symptoms, emphasizing the progressive nature of sexual dysfunction in MS patients [16]. Neuroimaging studies have provided insights into the neural correlates of ED in MS, revealing structural and functional abnormalities in brain regions involved in sexual arousal and response.

Peripheral Neuropathy

Peripheral neuropathy refers to damage or dysfunction of the peripheral nerves, which transmit signals between the central nervous system (CNS) and the rest of the body. This condition can profoundly affect erectile function, contributing to the development of erectile dysfunction (ED) in affected individuals [17].

Peripheral neuropathy encompasses a wide range of disorders that affect the peripheral nerves, leading to symptoms such as numbness, tingling, weakness, and pain in the extremities. This condition can arise from various causes, including diabetes mellitus, autoimmune diseases, infections, traumatic injuries, and exposure to toxins or medications. Peripheral neuropathy can disrupt neural signaling pathways involved in penile erection, thereby impairing erectile function.

The mechanism by which peripheral neuropathy contributes to ED involves the disruption of neural pathways responsible for initiating and maintaining penile erection. Peripheral nerves play a crucial role in transmitting signals from the brain and spinal cord to the penis, regulating blood flow and smooth muscle relaxation in the erectile tissue. Damage to these nerves disrupts this signaling process, resulting in insufficient blood flow to the penis and inadequate erectile response. Additionally, peripheral neuropathy can impair sensation in the genital region, reducing sexual arousal and diminishing the quality of erections.

Several studies have identified peripheral neuropathy as a significant contributing factor to ED. Research involving diabetic patients, who are particularly prone to peripheral neuropathy, has demonstrated a strong association between neuropathic changes and erectile dysfunction. For example, a study published in the Journal of Diabetes and its Complications found that diabetic men with peripheral neuropathy had a significantly higher prevalence of ED compared to those without neuropathy. Another study published in the Journal of Sexual Medicine reported that diabetic neuropathy was independently associated with ED severity, highlighting the impact of peripheral nerve damage on erectile function [18].

Moreover, research conducted in non-diabetic populations has also highlighted the link between peripheral neuropathy and ED. A study published in the International Journal of Impotence Research investigated the prevalence of peripheral neuropathy in men with ED of various etiologies and found that a significant proportion of patients exhibited signs of peripheral nerve dysfunction [19]. These findings underscore the importance of recognizing peripheral neuropathy as a potential cause of ED, particularly in individuals with underlying medical conditions or risk factors predisposing them to nerve damage.

Parkinson's disease

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra, a part of the brain crucial for controlling movement. This neuronal loss leads to the hallmark symptoms of PD: tremor, bradykinesia, rigidity, and postural instability. Beyond these motor symptoms, PD frequently manifests with a variety of non-motor symptoms, including cognitive impairment, mood disorders, autonomic dysfunction, and sleep disturbances. Among these non-motor symptoms, erectile dysfunction (ED) is particularly prevalent and distressing, affecting a significant proportion of men with PD.

The pathophysiology of ED in PD is multifactorial, involving both central and peripheral mechanisms. The degeneration of dopaminergic neurons leads to a decrease in dopamine levels, which plays a critical role in sexual arousal and erectile function. Dopamine is essential for initiating the neural signals that trigger the erectile response. In PD, diminished dopamine levels impair these signals, contributing to ED.

Furthermore, PD can cause autonomic dysfunction, affecting the autonomic nervous system (ANS), which regulates involuntary bodily functions, including blood flow to the penis. The ANS comprises the sympathetic and parasympathetic nervous systems, both of which are essential for normal erectile function. PD-induced autonomic dysfunction can disrupt the balance between these systems, leading to inadequate penile blood flow and impaired erection.

Additionally, PD-related psychological factors, such as depression and anxiety, further exacerbate ED. The chronic nature of PD and the associated disability can lead to significant psychological distress, which negatively impacts sexual function [20].

Several studies have explored the relationship between PD and ED, highlighting its prevalence and underlying mechanisms. A study found that 60-80% of men with PD reported experiencing ED, underscoring its commonality in this population. The study also emphasized the role of dopaminergic therapy in potentially improving erectile function, suggesting that dopamine replacement could partially mitigate ED symptoms [20].

Another study focused on the autonomic dysfunction in PD and its contribution to ED. The researchers used autonomic function tests and found significant abnormalities in men with PD, correlating these findings with the presence of ED. This study highlighted the importance of addressing autonomic dysfunction in managing ED in PD patients [21].

A more recent meta-analysis reviewed multiple studies on non-motor symptoms in PD, including ED. The analysis confirmed the high prevalence of ED in PD patients and emphasized the multifactorial nature of its etiology, involving neurogenic, autonomic, and psychological factors [22].

Ischemic stroke

Ischemic stroke, a condition resulting from the obstruction of blood flow to the brain, is a significant neurological event that can have profound effects on various bodily functions, including sexual health. An ischemic stroke occurs when a blood clot or other obstruction blocks an artery supplying blood to the brain, leading to the death of brain tissue in the affected area. This type of stroke can impact various neurological pathways, potentially leading to a wide array of complications, including erectile dysfunction (ED). The relationship between ischemic stroke and ED is multifaceted, involving both direct neurological damage and indirect effects on vascular and psychological health.

The mechanism by which ischemic stroke contributes to ED primarily involves the disruption of neural pathways essential for erectile function. Erections are controlled by a complex interaction between the central nervous system (CNS) and the peripheral nervous system (PNS). An ischemic stroke can damage the areas of the brain responsible for sexual arousal and penile erection, such as the hypothalamus and cerebral cortex. Moreover, strokes affecting the spinal cord or brainstem can impair the transmission of nerve signals from the brain to the penile nerves, resulting in reduced or absent erections.

Additionally, ischemic stroke often leads to secondary vascular issues, such as endothelial dysfunction and reduced blood flow, which are critical for maintaining an erection. The damage to the autonomic nervous system, which controls involuntary bodily functions including blood vessel dilation, can further exacerbate ED. Psychological factors following a stroke, such as depression, anxiety, and decreased self-esteem, also play a significant role in the onset and persistence of ED [23].

Numerous studies have identified ischemic stroke as a significant risk factor for the development of

ED. Research indicates that men who have experienced an ischemic stroke are at a higher risk of ED compared to those without a history of stroke. A study found that among men who had suffered a stroke, 64% reported experiencing ED, highlighting the substantial impact of stroke on sexual health [24]. Another study demonstrated that stroke patients had a higher prevalence of ED compared to the general population, with those suffering from right hemisphere strokes exhibiting more severe symptoms [25].

Congenital spinal abnormalities

Congenital spinal abnormalities encompass a range of structural defects in the spine present at birth, including conditions such as spina bifida, tethered cord syndrome, and congenital scoliosis. These anomalies can lead to significant neurological impairments due to the abnormal development of the spinal cord and its associated neural pathways. Such abnormalities may disrupt the normal function of nerves that are critical for various bodily functions, including sexual health and erectile function.

The mechanism by which congenital spinal abnormalities affect erectile function primarily involves the disruption of the neural pathways that mediate erection. Penile erection is a complex process that requires the integration of sensory input, central nervous system processing, and peripheral nervous system output. This process involves the activation of parasympathetic fibers (originating in the sacral spinal cord) that facilitate the relaxation of penile smooth muscles, allowing for increased blood flow and subsequent erection.

Congenital spinal abnormalities can interfere with this process in several ways:

- **Nerve Damage:** Structural deformities can cause direct damage to the nerves responsible for transmitting signals necessary for erection.
- **Impaired Signal Transmission:** Abnormalities in the spinal cord can hinder the transmission of signals from the brain to the sacral nerves, disrupting the communication required for initiating and maintaining an erection.
- **Vascular Complications:** Some congenital conditions may also affect blood vessels, further complicating the erectile process by impairing blood flow to the penile tissues. [26]

A study reported that men with spina bifida have a high prevalence of erectile dysfunction, primarily due to the neurogenic nature of their condition. The study found that about 75% of men with spina bifida experience some degree of erectile dysfunction, correlating with the severity and level of the spinal lesion [27].

Another study demonstrated that patients with tethered cord syndrome often experience neurological deficits affecting bladder, bowel, and sexual functions, including erectile dysfunction. Surgical intervention to release the tethered cord has been shown to improve erectile function in some cases, indicating a direct link between the spinal abnormality and ED [28].

Severe cases of congenital scoliosis, though less commonly linked to erectile dysfunction than other spinal conditions, can cause spinal cord compression and neurological deficits, including ED. A study in the European Spine Journal found that corrective surgery in these cases sometimes led to improved sexual function, indicating the influence of spinal alignment on neural integrity and erectile function.

Spinal Cord Injury

Spinal cord injury (SCI) is a debilitating condition resulting from trauma or disease affecting the spinal cord, leading to partial or complete loss of sensory and motor function below the level of injury. Among the numerous complications associated with SCI, erectile dysfunction (ED) is a prevalent and distressing issue for affected individuals. The extent of ED in SCI patients varies depending on the location and severity of the injury, but it remains a significant concern that affects the quality of life and psychological well-being of these individuals.

The mechanism by which SCI leads to ED involves the disruption of the neural pathways essential for penile erection. Erection is a neurovascular event that requires intact neural communication between the brain, spinal cord, and peripheral nerves. There are two types of erections: psychogenic and reflexogenic. Psychogenic erections are initiated by erotic or mental stimuli and involve neural signals from the brain through the spinal cord. Reflexogenic erections are triggered by direct physical stimulation and rely on the spinal reflex arc.

SCI can interrupt these pathways in several ways:
Upper Motor Neuron (UMN) Lesions: Injuries above the sacral segments of the spinal cord (typically above T12) can preserve reflexogenic erections but often impair psychogenic erections due to the disconnection of signals from the brain.
Lower Motor Neuron (LMN) Lesions: Injuries at or below the sacral segments (typically below T12) can impair reflexogenic erections due to damage to the reflex arc, although psychogenic erections may still occur if the connection to the brain remains intact.

The extent and type of ED depend on the level and completeness of the SCI. Complete injuries (total loss of function below the injury level) typically result in more severe ED compared to incomplete injuries (partial preservation of sensory or motor function) [29].

A study on men with SCI and found that 80% reported some degree of ED. The study highlighted the correlation between the level of injury and the type of erectile dysfunction experienced, with higher injuries predominantly affecting psychogenic erections and lower injuries affecting reflexogenic erections [30].

Other study investigated the prevalence of ED in men with SCI and found that 95% of participants experienced erectile issues, emphasizing the disruption of the neural pathways involved in erection due to spinal cord damage [31].

Another study reviewed sexual dysfunction in men with SCI and reported that the level and completeness of the injury were crucial determinants of erectile function, corroborating earlier findings that both UMN and LMN lesions contribute to ED through different mechanisms [32].

Pelvic and retroperitoneal surgery

Pelvic and retroperitoneal surgeries encompass a range of surgical procedures performed in the pelvic cavity and retroperitoneal space, including but not limited to prostatectomies, colorectal surgeries, bladder surgeries, and procedures involving the aorta and kidneys. These surgeries are often necessary for treating malignancies, benign growths, or structural abnormalities. However, they carry a significant risk of complications, including erectile dysfunction (ED), which can profoundly affect a patient's quality of life postoperatively.

The mechanism by which pelvic and retroperitoneal surgeries lead to ED primarily involves damage to the neurovascular structures essential for erectile function. The pelvic region houses the cavernous nerves, which play a crucial role in the neural pathways responsible for achieving and maintaining an erection. During surgeries, these nerves can be inadvertently damaged due to their proximity to the organs being operated on.

In particular, radical prostatectomy, which involves the removal of the prostate gland for prostate cancer, is well-known for its risk of causing ED. The surgery can lead to direct injury or traction on the cavernous nerves. Additionally, the blood vessels that supply the penile tissue may be compromised during these procedures, resulting in impaired blood flow essential for an erection.

Furthermore, surgeries in the retroperitoneal space can affect the autonomic nervous system, specifically the sympathetic and parasympathetic nerves, which are integral to the erectile process. Damage or disruption to these nerves can inhibit the signaling required for vascular engorgement of the penile tissue, thereby leading to ED [33].

Multiple studies have identified pelvic and retroperitoneal surgeries as significant risk factors for developing ED. For instance, a study highlighted that radical prostatectomy often leads to ED, with postoperative rates ranging from 25% to 75%, depending on the surgical technique and nerve-sparing approaches used. This study underscored the importance of nerve-sparing techniques in reducing the incidence of ED [34].

Similarly, a study evaluated the impact of colorectal surgery on sexual function and found that 35% of patients undergoing these procedures experienced new-onset ED. This study emphasized the role of intraoperative nerve damage as a primary cause of postoperative ED [35].

Cavernous Nerve Injury

Cavernous nerve injury is a significant cause of erectile dysfunction (ED), particularly prevalent in men undergoing pelvic surgeries such as radical prostatectomy for prostate cancer. The cavernous nerves, branches of the pelvic plexus, are responsible for the autonomic regulation of penile erection. These nerves carry parasympathetic fibers that induce the relaxation of smooth muscle in the penile arteries, facilitating increased blood flow and subsequent erection. Injury to these nerves disrupts this process, leading to impaired erectile function.

The mechanism through which cavernous nerve injury leads to ED primarily involves the disruption of neural signaling required for penile erection. Normally, the cavernous nerves release nitric oxide (NO), a crucial neurotransmitter that induces the relaxation of smooth muscle in the corpora cavernosa (the erectile tissue of the penis). NO activates the enzyme guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) levels, which in turn causes smooth muscle relaxation and vasodilation, allowing blood to fill the penile tissues and produce an erection.

When the cavernous nerves are damaged, the production and release of NO are significantly reduced or halted. This leads to insufficient smooth muscle relaxation and reduced blood flow into the corpora cavernosa, resulting in an inability to achieve or maintain an erection. The injury can be partial or complete, and the extent of erectile dysfunction correlates with the severity of nerve damage. Additionally, nerve injury can lead to fibrosis and structural changes within the penile tissues, further exacerbating erectile difficulties [36].

Numerous studies have identified cavernous nerve injury as a key cause of ED, particularly in the context of prostate cancer treatment. For instance, other study among the first to highlight the association between radical prostatectomy and subsequent ED, attributing it to inadvertent damage to the cavernous nerves during surgery. Their pioneering work led to the

development of nerve-sparing surgical techniques aimed at preserving erectile function [37].

Subsequent research has reinforced these findings. A study demonstrated that men who underwent nerve-sparing prostatectomy had significantly better postoperative erectile function compared to those who had non-nerve-sparing surgery [38].

Risk Factors

HTLV-1

Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus primarily transmitted through sexual contact, blood transfusions, and from mother to child during breastfeeding. It is endemic in certain regions such as Japan, the Caribbean, parts of Africa, and South America. HTLV-1 is associated with several serious diseases, including adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HAM/TSP, a chronic, progressive disease, results in inflammation and degeneration of the spinal cord, significantly impacting the nervous system and potentially contributing to erectile dysfunction (ED).

HTLV-1's role in erectile dysfunction primarily revolves around its impact on the neurological system. The virus infects CD4+ T-cells, leading to chronic inflammation and demyelination in the central nervous system, particularly the spinal cord. This neuroinflammation impairs the neural pathways critical for initiating and maintaining erections. Specifically, the autonomic and sensory nerves involved in the erectile response are compromised, leading to reduced neural input and subsequent erectile dysfunction. Additionally, HTLV-1 can cause vascular inflammation, further impairing penile blood flow essential for achieving an erection [39].

One study investigated sexual dysfunction in patients with HAM/TSP, finding a high prevalence of ED among male participants. The study demonstrated that the neurological impairment caused by HTLV-1 was a significant factor in the development of ED [40].

Another study reported that, the sexual function of male patients with HAM/TSP was evaluated using the International Index of Erectile Function (IIEF). Results indicated a substantial decline in erectile function scores among HTLV-1-infected individuals, correlating the severity of spinal cord involvement with the degree of erectile dysfunction. Findings also revealed that the virus-induced damage to these nerve pathways significantly contributed to the onset and progression of ED in affected individuals [41].

Alcohol and Drug Use

Alcohol and drug use are significant lifestyle factors contributing to the progression of erectile dysfunction (ED). Excessive consumption of alcohol and the use of various recreational drugs have been linked to impaired sexual performance and increased incidence of ED. Alcohol is a central nervous system depressant that, in large amounts, can interfere with sexual function, while recreational drugs like marijuana, cocaine, opioids, and others affect the body in ways that can compromise erectile capabilities.

Alcohol: Alcohol affects erectile function through multiple pathways. Acute alcohol consumption can cause transient ED by depressing the central nervous system, leading to reduced sexual arousal and decreased blood flow to the penis. Chronic alcohol abuse, however, has more profound effects. It leads to liver damage, which results in hormonal imbalances such as decreased testosterone levels. Additionally, chronic alcohol use causes neuropathy and damages the blood vessels, both of which are crucial for erectile function. The overall result is an impaired ability to achieve and maintain an erection.

Drugs: Different recreational drugs affect erectile function through various mechanisms:

Marijuana: Marijuana use can contribute to erectile dysfunction (ED) through several mechanisms. The active ingredient, THC, can interfere with the body's hormone balance, potentially lowering testosterone levels, which are crucial for sexual function. Additionally, marijuana can impair the nervous system, affecting the neural pathways involved in arousal and erection. Chronic use may also lead to vascular changes, reducing blood flow to the penis, and increasing the risk of ED. Psychological effects such as anxiety and altered perception can further disrupt sexual performance, contributing to erectile difficulties.

Cocaine: This stimulant drug causes erectile dysfunction (ED) through multiple mechanisms. It acts as a potent vasoconstrictor, reducing blood flow to the penis, which is essential for achieving and maintaining an erection. Cocaine use can also damage the blood vessels and impair the cardiovascular system, further exacerbating ED. Additionally, cocaine affects the central nervous system by altering dopamine levels, which can disrupt the neural pathways involved in sexual arousal.

Opioids: These drugs suppress the hypothalamic-pituitary-gonadal axis, resulting in lower testosterone levels, which are crucial for normal sexual function. Opioids also depress the central nervous system, affecting the neural pathways that facilitate arousal and erection. Chronic opioid use can cause vascular damage, reducing blood flow to the penis. Additionally, the sedative effects of opioids can decrease libido and sexual performance.

Amphetamines: They stimulate the release of neurotransmitters like dopamine and norepinephrine. These stimulants can cause vasoconstriction and lead to

long-term cardiovascular damage, contributing to ED [42].

Numerous studies have identified alcohol and drug use as significant risk factors for the progression of ED. A study published highlighted that men who consumed alcohol excessively were more likely to experience ED compared to non-drinkers. The study showed that chronic alcohol uses significantly reduced erectile function due to its detrimental effects on vascular and neurological health [43].

Another study found a strong correlation between drug use and ED. The study indicated that men who used recreational drugs had a higher prevalence of ED. Cocaine users, in particular, were shown to have higher rates of ED due to the vasoconstrictive properties of the drug, which compromise blood flow to the penis [44].

Certain Medications

Erectile dysfunction (ED) is a multifactorial condition that can be exacerbated by certain medications. These drugs, while effective in treating various primary conditions, can have adverse effects on erectile function. Common medications linked to ED include antihypertensives, antidepressants, antipsychotics, and medications for prostate conditions. Understanding how these medications contribute to ED is crucial for managing the condition in patients who rely on these drugs for other health issues.

Antihypertensives: Medications such as beta-blockers, thiazide diuretics, and ACE inhibitors are used to manage high blood pressure. They can cause ED by reducing blood flow to the penis, interfering with the sympathetic nervous system, or altering hormonal levels. Beta-blockers, for example, decrease the force of heart contractions and reduce blood pressure, which can limit the necessary blood flow for an erection.

Antidepressants: Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) are commonly prescribed for depression and anxiety. These medications can cause ED by increasing serotonin levels, which may inhibit sexual desire and interfere with the neurochemical processes involved in achieving an erection. Additionally, they can cause hormonal imbalances that negatively impact sexual function.

Antipsychotics: Drugs used to treat psychiatric disorders, such as schizophrenia and bipolar disorder, can lead to ED through various mechanisms. They often block dopamine receptors, reducing libido and sexual pleasure. Furthermore, they can increase prolactin levels, leading to decreased testosterone levels and impaired erectile function.

Medications for Prostate Conditions: Drugs like finasteride and dutasteride, used for benign prostatic hyperplasia (BPH) and hair loss, can cause ED by inhibiting the conversion of testosterone to dihydrotestosterone (DHT). This hormonal alteration can diminish sexual drive and erectile capability [45].

Numerous studies have identified these medications as risk factors for the progression of ED. A study found that men taking antihypertensive medications had a significantly higher incidence of ED compared to those not on these drugs. The study highlighted the need for regular screening and potential medication adjustments to mitigate this side effect [46].

Research in Psychopharmacology identified SSRIs as a major contributor to sexual dysfunction, including ED, in both short-term and long-term users. The study suggested considering alternative treatments or adjunctive therapies to counteract these effects [47].

Management of Neurogenic Erectile Dysfunction

Managing erectile dysfunction requires a comprehensive approach which is tailored to address its diverse causes, including neurological, vascular, physiological, psychological, and other factors. Various treatment options range from oral pharmacotherapy to surgical interventions, each with its own indications and considerations.

Oral pharmacotherapies are generally considered as the first choice for neurogenic ED and retrograde ejaculation. PDE5 inhibitors such as sildenafil, tadalafil, avanafil, and vardenafil are commonly used as first-line treatment for ED. While they have shown efficacy in patients with spinal cord injury (SCI) based on available clinical data, results in other neurogenic conditions like MS and PD are mixed. These medications do not induce erections but help maintain them once initiated. Dosage adjustment may be necessary depending on the severity of neurological damage. Although 10 mg tadalafil seem to be more effective than 50 mg sildenafil, there is a distinct lack of high-level studies regarding their safety and side effects at any dosage. Fampridine is a potassium channel inhibitor used primarily for neurogenic spasticity. It has shown some promise in improving erectile functions in patients with SCI and/or MS. However, its use is limited due to significant adverse effects, leading to high discontinuation rates. Apomorphine is a D1/D2 dopamine antagonist which can potentially aid in achieving psychogenic erections by acting on the hypothalamus and possibly the spinal cord. Its overall success rate is low, and the effectiveness data is limited due to heterogeneous populations and placebo-controlled trials.

Tertiary Therapies or Surgical Interventions are taken into consideration when first-line therapies fall short. Intraurethral Alprostadil involves administering a vaso-active agent directly into the urethra. It is available in medicated pellet and cream forms. This method can

induce erections by increasing blood flow to the penis, but it is generally less effective than intra-cavernosal injections. Limited studies suggest it might be effective in patients with SCI, though erections achieved this way were often less rigid. Common side effects include urethral pain and hypotension, particularly in patients with higher spinal cord lesions. Despite its limitations, intraurethral alprostadil remains a viable alternative for patients who cannot use other forms of ED treatment. Vacuum Erection Devices (VEDs) create a vacuum around the penis to draw blood into the corpora cavernosa which induces an erection that is maintained with a constriction ring at the base of the penis. These devices are generally effective, with a study reporting that after three months of use, 93% of men and 83% of their partners found the erections sufficient for vaginal penetration which lasted about 18 minutes. Satisfaction rates, however, declined over time, with only 41% of men and 45% of women satisfied after six months. The most common complaint was the early loss of erection rigidity. While complications like bruising, pain, and petechiae can occur, more serious issues like tissue ischemia are less common, particularly when the devices are used correctly. Despite these drawbacks, 60% of men and 42% of their partners reported improvements in their sexual lives which highlights the potential benefits of VEDs in managing ED. Intracavernosal Injections (ICIs) involve directly injecting vaso-active agents like alprostadil, papaverine, and phentolamine into the penile corpora cavernosa to induce an erection. Although the introduction of phosphodiesterase type 5 inhibitors (PDE5Is) has made this method less common, ICIs remain a vital option when oral medications are ineffective. Studies indicate that ICIs are effective in 88% of patients with spinal cord injuries (SCI), despite a complication rate of 13.3%. The most severe side effects include prolonged erection (priapism), ecchymosis, and fibrosis. Initial doses are kept small to avoid complications, particularly since many neurogenic patients lack vasculogenic factors. Despite the risks, ICIs provide a reliable alternative, with the added advantage of being safe for use alongside nitrates, unlike PDE5Is. This makes ICIs a valuable treatment for those who cannot achieve satisfactory results with oral therapies.

Low-Intensity Extra-Corporeal Shock Waves Treatment is an emerging therapy for erectile dysfunction (ED) that uses shock waves to stimulate angiogenesis and tissue regeneration. While the exact mechanism remains unclear, studies suggest that LI-ESWT promotes the up-regulation of vascular endothelial growth factor (VEGF), leading to improved blood flow and potentially nerve regeneration. Research indicates promising results, although standardized protocols and equipment are still lacking. For neurogenic ED experimental data in animal models show potential benefits, including reduced cell death and improved sensory functions. However, these findings have yet to be confirmed in human trials, indicating that more research is needed before LI-ESWT can be routinely applied in clinical practice for neurogenic ED.

Regenerative therapies include stem cell therapy and platelet-rich plasma (PRP). They offer promising approaches to treating ED by repairing underlying tissue and nerve damage. Stem cells can regenerate various cell types and secrete growth factors, with mesenchymal stem cells (MSCs) and adipose-derived stem cells showing significant potential in preclinical studies. PRP is rich in growth factors, and can enhance tissue repair and regeneration. While these therapies are still experimental and primarily studied in animal models, they aim to address the root causes of neurogenic ED rather than just managing symptoms. Further research is needed to confirm their safety and efficacy for clinical use.

Surgical implantation of penile prostheses is considered the last and definitive treatment for ED when other therapies have failed or are unsuitable. There are two main types of implants: semi-rigid (malleable) and inflatable (two or three-piece) implants. These devices offer reliable solutions for achieving erections, but they are not without complications. Mechanical failure and infection are the primary concerns, with infection rates up to 2-3% in low-risk patients, even when using antibiotic-impregnated or hydrophilic-coated devices. Neurogenic patients with SCI face higher complication rates due to factors such as lack of dexterity, frequent urinary tract infections, and skin ulcers. Diabetics with ED require special care as they are at higher risk of developing infection after prostheses implantation due to their poor healing response. Despite these risks, penile prostheses can significantly improve the quality of life by restoring sexual function and addressing other issues like urinary incontinence. Proper patient selection, thorough preoperative counseling, and strict postoperative care are essential to minimize complications and enhance patient satisfaction [48-50].

CONCLUSION

Erectile dysfunction (ED) is a multifaceted condition often exacerbated by various neurological disorders and associated risk factors. Neurological causes such as multiple sclerosis, Parkinson's disease, ischemic stroke, congenital spinal abnormalities, and spinal cord injuries significantly disrupt the neural pathways critical for erectile function. These disorders impair both central and peripheral nervous system components, leading to ED. Additionally, chronic conditions like diabetes mellitus, hypertension, hyperlipidemia, and cardiovascular diseases further contribute to ED by compromising vascular health and blood flow to the penis. Lifestyle factors including smoking, excessive alcohol consumption, obesity, and sedentary behavior exacerbate these issues by promoting vascular and hormonal imbalances. Psychological stressors such as anxiety, depression, and relationship problems add another layer of complexity to ED's

etiology. Pelvic and retroperitoneal surgeries, cavernous nerve injuries, and certain medications, including antihypertensives, antidepressants, and antipsychotics, also play significant roles in the progression of ED by directly affecting the neural and vascular mechanisms involved in erection. Effective management of ED thus requires a comprehensive and multidisciplinary approach, addressing both the neurological and systemic contributors to the condition to improve patient outcomes and quality of life.

REFERENCE

1. Anderson, K. D. (2004). Targeting recovery: priorities of the spinal cord-injured population. *Journal of neurotrauma*, *21*(10), 1371-1383.
2. Basson, R., & Schultz, W. W. (2007). Sexual sequelae of general medical disorders. *The Lancet*, *369*(9559), 409-424.
3. Heath, R. G. (1964). Pleasure response of human subjects to direct stimulation of the brain: Physiologic and psychodynamic considerations. *RG Heath (Ed.), The role of pleasure in behavior, New York (Harper & Row) 1964, pp. 219-245*.
4. Redouté, J., Stoléru, S., Grégoire, M. C., Costes, N., Cinotti, L., Lavenne, F., ... & Pujol, J. F. (2000). Brain processing of visual sexual stimuli in human males. *Human brain mapping*, *11*(3), 162-177.
5. Holstege, G., Georgiadis, J. R., Paans, A. M., Meiners, L. C., van der Graaf, F. H., & Reinders, A. S. (2003). Brain activation during human male ejaculation. *Journal of Neuroscience*, *23*(27), 9185-9193.
6. Park, K., Seo, J. J., Kang, H. K., Ryu, S. B., Kim, H. J., & Jeong, G. W. (2001). A new potential of blood oxygenation level dependent (BOLD) functional MRI for evaluating cerebral centers of penile erection. *International Journal of Impotence Research*, *13*(2), 73-81.
7. Arnow, B. A., Desmond, J. E., Banner, L. L., Glover, G. H., Solomon, A., Polan, M. L., ... & Atlas, S. W. (2002). Brain activation and sexual arousal in healthy, heterosexual males. *Brain*, *125*(5), 1014-1023.
8. Karama, S., Lecours, A. R., Leroux, J. M., Bourgouin, P., Beaudoin, G., Joubert, S., & Beauregard, M. (2002). Areas of brain activation in males and females during viewing of erotic film excerpts. *Human brain mapping*, *16*(1), 1-13.
9. Hamann, S., Herman, R. A., Nolan, C. L., & Wallen, K. (2004). Men and women differ in amygdala response to visual sexual stimuli. *Nature neuroscience*, *7*(4), 411-416.
10. Ferretti, A., Caulo, M., Del Gratta, C., Di Matteo, R., Merla, A., Montorsi, F., ... & Romani, G. L. (2005). Dynamics of male sexual arousal: distinct components of brain activation revealed by fMRI. *Neuroimage*, *26*(4), 1086-1096.
11. Georgiadis, J. R., Kortekaas, R., Kuipers, R., Nieuwenburg, A., Pruim, J., Reinders, A. S., & Holstege, G. (2006). Regional cerebral blood flow changes associated with clitorally induced orgasm in healthy women. *European Journal of Neuroscience*, *24*(11), 3305-3316.
12. Mouras, H., Stoléru, S., Bittoun, J., Glutron, D., Pélégrini-Issac, M., Paradis, A. L., & Burnod, Y. (2003). Brain processing of visual sexual stimuli in healthy men: a functional magnetic resonance imaging study. *Neuroimage*, *20*(2), 855-869.
13. Araki, I., & Kuno, S. (2000). Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. *Journal of Neurology, Neurosurgery & Psychiatry*, *68*(4), 429-433.
14. Steer, R. A., Ball, R., Ranieri, W. F., & Beck, A. T. (1999). Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients. *Journal of clinical psychology*, *55*(1), 117-128.
15. Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology*, *33*(11), 1444-1444.
16. Zorzon, M. A. R. I. N. O., Zivadinov, R., Bosco, A., Bragadin, L. M., Moretti, R., Bonfigli, L., ... & Cazzato, G. (1999). Sexual dysfunction in multiple sderosis: a case-control study. 1. Frequency and comparison of groups. *Multiple Sclerosis Journal*, *5*(6), 418-427.
17. Hicks, C. W., & Selvin, E. (2019). Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. *Current diabetes reports*, *19*, 1-8.
18. Hicks, C. W., Wang, D., Daya, N. R., Windham, B. G., Ballantyne, C. M., Matsushita, K., & Selvin, E. (2020). Associations of cardiac, kidney, and diabetes biomarkers with peripheral neuropathy among older adults in the atherosclerosis risk in communities (ARIC) study. *Clinical chemistry*, *66*(5), 686-696.
19. Nehra, A., & Moreland, R. B. (2001). Neurologic erectile dysfunction. *Urologic Clinics of North America*, *28*(2), 289-308.
20. Tolosa, E., Ebersbach, G., Ferreira, J. J., Rascol, O., Antonini, A., Foltynie, T., ... & Lees, A. (2021). The Parkinson's Real-World Impact Assessment (PRISM) study: A European survey of the burden of Parkinson's disease in patients and their carers. *Journal of Parkinson's Disease*, *11*(3), 1309-1323.
21. Weintraub, D., Hoops, S., Shea, J. A., Lyons, K. E., Pahwa, R., Driver-Dunckley, E. D., ... & Voon, V. (2009). Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. *Movement disorders: official journal of the Movement Disorder Society*, *24*(10), 1461-1467.
22. Sherbourne, C. D. (1992). 11. Social functioning: Sexual problems measures. *Measuring functioning and well-being: The Medical Outcomes Study approach*, *194*.
23. Zhao, B., Hong, Z., Wei, Y., Yu, D., Xu, J., & Zhang, W. (2019). Erectile dysfunction predicts cardiovascular events as an independent risk factor: a systematic review and meta-analysis. *The Journal of Sexual Medicine*, *16*(7), 1005-1017.

24. Chung, S. D., Chen, Y. K., Lin, H. C., & Lin, H. C. (2011). Increased risk of stroke among men with erectile dysfunction: a nationwide population-based study. *The journal of sexual medicine*, *8*(1), 240-246.
25. Jung, J. H., Kam, S. C., Choi, S. M., Jae, S. U., Lee, S. H., & Hyun, J. S. (2008). Sexual dysfunction in male stroke patients: correlation between brain lesions and sexual function. *Urology*, *71*(1), 99-103.
26. Gatti, C., Del Rossi, C., Ferrari, A., Casolari, E., Casadio, G., & Scire, G. (2009). Predictors of successful sexual partnering of adults with spina bifida. *The Journal of urology*, *182*(4S), 1911-1916.
27. Lee, N. G., Andrews, E., Rosoklija, I., Logvinenko, T., Johnson, E. K., Oates, R. D., & Estrada Jr, C. R. (2015). The effect of spinal cord level on sexual function in the spina bifida population. *Journal of pediatric urology*, *11*(3), 142-e1.
28. Lindehall, B., Möller, A., Hjälmås, K., Lindehall, B., Möller, A., Hjälmås, K., ... & Abrahamsson, K. (2008). Psychosocial factors in teenagers and young adults with myelomeningocele and clean intermittent catheterization. *Scandinavian journal of urology and nephrology*, *42*(6), 539-544.
29. Renganathan, R., Suranjan, B., & Kurien, T. (1997). Comparison of transdermal nitroglycerin and intracavernous injection of papaverine in the treatment of erectile dysfunction in patients with spinal cord lesions. *Spinal Cord*, *35*(2), 99-103.
30. Kapoor, V. K., Chahal, A. S., Jyoti, S. P., Mundkur, Y. J., Kotwal, S. V., & Mehta, V. K. (1993). Intracavernous papaverine for impotence in spinal cord injured patients. *Spinal Cord*, *31*(10), 675-677.
31. Bodner, D. R., Leffler, B., & Frost, F. (1992). The role of intracavernous injection of vasoactive medications for the restoration of erection in spinal cord injured males: a three year follow up. *Spinal Cord*, *30*(2), 118-120.
32. Dietzen, C. J., & Lloyd, L. K. (1992). Complications of intracavernous injections and penile prostheses in spinal cord injured men. *Archives of physical medicine and rehabilitation*, *73*(7), 652-655.
33. Nathan, A., Shukla, S., Sinha, A., Sivathasan, S., Rashid, A., Rassam, J., ... & Lamb, B. W. (2021). Immediate post-operative PDE5i therapy improves early erectile function outcomes after robot assisted radical prostatectomy (RARP). *Journal of Robotic Surgery*, 1-7.
34. Sooriakumaran, P., Pini, G., Nyberg, T., Derogar, M., Carlsson, S., Stranne, J., ... & Wiklund, P. N. (2018). Erectile function and oncologic outcomes following open retropubic and robot-assisted radical prostatectomy: results from the laparoscopic prostatectomy robot open trial. *European urology*, *73*(4), 618-627.
35. Ficarra, V., Novara, G., Ahlering, T. E., Costello, A., Eastham, J. A., Graefen, M., ... & Montorsi, F. (2012). Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. *European urology*, *62*(3), 418-430.
36. Sauzeau, V., Le Jeune, H., Cario-Toumaniantz, C., Smolenski, A., Lohmann, S. M., Bertoglio, J., ... & Loirand, G. (2000). Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. *Journal of Biological Chemistry*, *275*(28), 21722-21729.
37. Lasker, G. F., Pankey, E. A., Allain, A. V., Murthy, S. N., Stasch, J. P., & Kadowitz, P. J. (2013). The selective Rho-kinase inhibitor azaindole-1 has long-lasting erectile activity in the rat. *Urology*, *81*(2), 465-e7.
38. Löhn, M., Plettenburg, O., Ivashchenko, Y., Kannt, A., Hofmeister, A., Kadereit, D., ... & Ruetten, H. (2009). Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. *Hypertension*, *54*(3), 676-683.
39. Castro, N. M., Rodrigues Jr, W., Freitas, D. M., Muniz, A., Oliveira, P., & Carvalho, E. M. (2007). Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-I carriers. *Urology*, *69*(5), 813-818.
40. Rocha, P. N., Rehem, A. P., Santana, J. F., Castro, N., Muniz, A. L., Salgado, K., ... & Carvalho, E. M. (2007). The cause of urinary symptoms among Human T Lymphotropic Virus Type I (HLTV-I) infected patients: a cross sectional study. *BMC infectious diseases*, *7*, 1-7.
41. Oliveira, P., Castro, N. M. D., & Carvalho, E. M. (2007). Urinary and sexual manifestations of patients infected by HTLV-I. *Clinics*, *62*, 191-196.
42. Wing, J. K., Babor, T., Brugha, T. S., Burke, J., Cooper, J. E., Giel, R., ... & Sartorius, N. (1990). SCAN: schedules fonr clinical assessment in neuropsychiatry. *Archives of general psychiatry*, *47*(6), 589-593.
43. World Health Organization. The ICD-10 classification of mental and behavioral disorders: Diagnostic criteria for research. Geneva: World Health Organization; 1993. [Google Scholar]
44. Jensen, S. B. (1984). Sexual function and dysfunction in younger married alcoholics: A comparative study. *Acta Psychiatrica Scandinavica*, *69*(6), 543-549.
45. MacADAMS, M. R., WHITE, R. H., & CHIPPS, B. E. (1986). Reduction of serum testosterone levels during chronic glucocorticoid therapy. *Annals of internal medicine*, *104*(5), 648-651.
46. Huyghe, E., Zairi, A., Nohra, J., Kamar, N., Plante, P., & Rostaing, L. (2007). Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. *Transplant International*, *20*(4), 305-311.
47. Moreno-Pérez, O., Escoín, C., Serna-Candel, C., Picó, A., Alfayate, R., Merino, E., ... & Portilla, J. (2010). Risk factors for sexual and erectile

dysfunction in HIV-infected men: the role of protease inhibitors. *Aids*, *24*(2), 255-264.

48. Thomas, C., & Konstantinidis, C. (2021). Neurogenic erectile dysfunction. where do we stand?. *Medicines*, *8*(1), 3.
49. Nguyen, H. M. T., Gabrielson, A. T., & Hellstrom, W. J. (2017). Erectile dysfunction in young men—a review of the prevalence and risk factors. *Sexual medicine reviews*, *5*(4), 508-520.
50. Fode, M., Krogh-Jespersen, S., Brackett, N. L., Ohl, D. A., Lynne, C. M., & Sønksen, J. (2012). Male sexual dysfunction and infertility associated with neurological disorders. *Asian journal of andrology*, *14*(1), 61.